[1] [1] RIAZI K, AZHARI H, CHARETTE J H, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7(9): 851-861.

[2] [2] YOUNOSSI Z M, KOENIG A B, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84.

[3] [3] LUDWIG J, VIGGIANO T R, MCGILL D B, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease[J]. Mayo Clin Proc, 1980, 55(7): 434-438.

[4] [4] POWELL E E, WONG V W, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224.

[5] [5] ESLAM M, NEWSOME P N, SARIN S K, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209.

[6] [6] RINELLA M E, LAZARUS J V, RATZIU V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol, 2023, 79(6): 1542-1556.

[7] [7] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. J Hepatol, 2024, 81(3): 492-542.

[9] [9] FAN J G, XU X Y, YANG R X, et al. Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (version 2024)[J]. J Clin Transl Hepatol, 2024, 12(11): 955-974.

[10] [10] BOYLE M, MASSON S, ANSTEE Q M. The bidirectional impacts of alcohol consumption and the metabolic syndrome: cofactors for progressive fatty liver disease[J]. J Hepatol, 2018, 68(2): 251-267.

[11] [11] ISRAELSEN M, TORP N, JOHANSEN S, et al. MetALD: new opportunities to understand the role of alcohol in steatotic liver disease[J]. Lancet Gastroenterol Hepatol, 2023, 8(10): 866-868.

[12] [12] KIM D, KONYN P, SANDHU K K, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States[J]. J Hepatol, 2021, 75(6): 1284-1291.

[13] [13] NGUYEN V H, LE M H, CHEUNG R C, et al. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD[J]. Clin Gastroenterol Hepatol, 2021, 19(10): 2172-2181. e6.

[14] [14] YOUNOSSI Z M, PAIK J M, AL SHABEEB R, et al. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?[J]. Hepatology, 2022, 76(5): 1423-1437.

[15] [15] ZHAO Q W, DENG Y L. Comparison of mortality outcomes in individuals with MASLD and/or MAFLD[J]. J Hepatol, 2024, 80(2): e62-e64.

[16] [16] LI M Q, XIE W. Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes?[J]. J Hepatol, 2024, 80(2): e53-e54.

[17] [17] YOON E L, JUN D W. Waiting for the changes after the adoption of steatotic liver disease[J]. Clin Mol Hepatol, 2023, 29(4): 844-850.

[18] [18] PLATEK A E, SZYMANSKA A. Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor[J]. Clin Exp Hepatol, 2023, 9(3): 187-192.

[19] [19] KOUVARI M, VALENZUELA-VALLEJO L, GUATIBONZA-GARCIA V, et al. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: results from a large multi-center study[J]. Metabolism, 2023, 147: 155666.

[20] [20] YOUNOSSI Z M, PAIK J M, STEPANOVA M, et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease[J]. J Hepatol, 2024, 80(5): 694-701.